Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
660.49
+21.06 (3.29%)
At close: Aug 13, 2025, 4:00 PM
662.86
+2.37 (0.36%)
After-hours: Aug 13, 2025, 7:59 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $15.56B in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
10.80
Revenue / Employee
$1,133,151
Employees
47,000
Market Cap
592.95B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
LLY News
- 7 hours ago - Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst - Benzinga
- 18 hours ago - Lilly launches Mounjaro pen in India priced at $160 - Reuters
- 1 day ago - These Eli Lilly executives have been scooping up stock after its big drop - Market Watch
- 1 day ago - Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications - Reuters
- 1 day ago - Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me' - Benzinga
- 1 day ago - 2 All-American Dividend Gems To Buy Before The Market Wakes Up - Seeking Alpha
- 4 days ago - Eli Lilly: Another Not-To-Miss Dip - Seeking Alpha
- 5 days ago - Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization - GlobeNewsWire